Option Care, ALS Association Partner to Offer Radicava Home Infusion Services

Option Care, ALS Association Partner to Offer Radicava Home Infusion Services

Option Care Enterprises, a Chicago-based independent provider of home and alternate treatment site infusion services, has partnered with the ALS Association to offer Radicava (edaravone) treatment from the comfort of their homes.

To date, more than 100 amyotrophic lateral sclerosis (ALS) patients are already receiving Radicava — the first ALS therapy approved by the U.S. Food and Drug Administration (FDA) in more than 20 years.

Radicava is administered intravenously into the bloodstream in 28-day cycles. Because infusions can be done at home, the FDA’s approval of the drug has led to increasing demand for home infusion services.

Option Care not only provides Radical, but also a nutrition support program and tube feeding for people living with the condition.

“We look forward to this new partnership with the ALS Association and the ability to be part of providing education, support and services to those living with the disease,” John Rademacher, the company’s CEO, said in a press release.

“We’re deeply grateful for Option Care’s willingness to support our mission of helping people with ALS and their families,” added Calaneet Balas, executive vice president of strategy at the ALS Association.

Radicava, developed by Mitsubishi Tanabe Pharma to slow the decline of physical functioning in ALS patients, is marketed in the United States by MT Pharma America.

Radicava is a free radical scavenger. Free radicals occur as part of the normal cellular process of human energy production and are usually quickly eliminated. But if they remain inside, they can cause oxidative stress, believed to be one of the causes of nerve cell death in ALS.

Radicava has a neuroprotective effect, slowing the progression of ALS by removing free radicals from the nervous system. In a Phase 3 clinical trial (NCT01492686), Radicava was shown to reduce by 33 percent the decline in the ALSFRS-R score compared to those taking placebo after six months of treatment.

These significant results appeared in The Lancet Neurology and served as grounds for the FDA’s approval of Radical in May 2017.

10 comments

  1. Gary Moser says:

    My wife has been waiting almost 2-months for Option Care to complete the paperwork for her home IV infusion. We have TriCare insurance which approved the treatment in just a few days, so it has not been an insurance hold-up. Option Care seems largely understaffed and unprepared to quickly provide services. Over two months just to start treatment is an eternity with ALS diagnosis. On top of that Option Care submitted insurance codes that are on the government “do not pay list” (for Medicare and TriCare), which seems like they didn’t to their homework or are not experienced in medical coding. Still waiting on Option Care as of today. I’ve been calling them 3-4 times a week for updates. We opted to just pay the out of pocket costs to not delay treatment, hopefully we’ll hear something soon.

  2. Thomas Harrison says:

    Time to contact your congressmen and WH about the fsilire of this organization to process the medical care that is taking two months. Als patients need quick action.

  3. My husband started the home infusion on Saturday 11/11/17. We have been very happy with Option Care and have had no issues with insurance or Option Care. So sorry there are so many of you that have had issues. Hopefully, they will be resolved soon and your loved ones can start getting the treatment they need. Regards..

  4. Cindy says:

    I am in same situation, waiting but in Colorado. We have no infusion center here to come on board because of they do not have proper billing code. Someone needs to get doctors, infusion centers up to speed! Every month is vital to us patients with ALS.

  5. Dave Siegers says:

    I’m very pleased with the service I’ve been given. I was originally denied by BCBS but after appealing I was approved. Then things happened quickly. No adverse side effects for me. Thank God!

  6. John Kracik says:

    I will the starting radicava on December 11th. Has anybody seen any of the side effects and which ones. Has anyone notice any kind of improvement. Is there a Blog on the internet referencing radicava.

    • Dave Siegers says:

      I’m on my second round now. I didn’t have any negative effects from the treatment, but I think it is to early to notice any positive effects.

Leave a Comment

Your email address will not be published. Required fields are marked *